EE200200712A - Puriinderivaadid - Google Patents

Puriinderivaadid

Info

Publication number
EE200200712A
EE200200712A EEP200200712A EEP200200712A EE200200712A EE 200200712 A EE200200712 A EE 200200712A EE P200200712 A EEP200200712 A EE P200200712A EE P200200712 A EEP200200712 A EE P200200712A EE 200200712 A EE200200712 A EE 200200712A
Authority
EE
Estonia
Prior art keywords
purine derivatives
purine
derivatives
Prior art date
Application number
EEP200200712A
Other languages
English (en)
Estonian (et)
Inventor
John Mantell Simon
Marina Monaghan Sandra
Thomas Stephenson Peter
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200200712A publication Critical patent/EE200200712A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
EEP200200712A 2000-06-27 2001-06-14 Puriinderivaadid EE200200712A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (fr) 2000-06-27 2001-06-14 Derives de purine

Publications (1)

Publication Number Publication Date
EE200200712A true EE200200712A (et) 2004-06-15

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200712A EE200200712A (et) 2000-06-27 2001-06-14 Puriinderivaadid

Country Status (43)

Country Link
EP (1) EP1296996B1 (fr)
JP (1) JP2004501929A (fr)
KR (1) KR20030036248A (fr)
CN (1) CN1432020A (fr)
AP (1) AP1372A (fr)
AR (1) AR028759A1 (fr)
AT (1) ATE267836T1 (fr)
AU (1) AU2001264164A1 (fr)
BG (1) BG107171A (fr)
BR (1) BR0111912A (fr)
CA (1) CA2412564C (fr)
CZ (1) CZ20023992A3 (fr)
DE (1) DE60103537T2 (fr)
DK (1) DK1296996T3 (fr)
DO (1) DOP2001000195A (fr)
EA (1) EA200201291A1 (fr)
EC (1) ECSP024396A (fr)
EE (1) EE200200712A (fr)
ES (1) ES2220775T3 (fr)
GB (1) GB0015727D0 (fr)
GT (1) GT200100119A (fr)
HR (1) HRP20020995A2 (fr)
HU (1) HUP0301389A3 (fr)
IL (1) IL152529A0 (fr)
IS (1) IS6580A (fr)
MA (1) MA26918A1 (fr)
MX (1) MXPA03000078A (fr)
NO (1) NO20025975D0 (fr)
NZ (1) NZ521867A (fr)
OA (1) OA12294A (fr)
PA (1) PA8521001A1 (fr)
PE (1) PE20020213A1 (fr)
PL (1) PL361384A1 (fr)
PT (1) PT1296996E (fr)
PY (1) PY0115244A (fr)
SI (1) SI1296996T1 (fr)
SK (1) SK17332002A3 (fr)
SV (1) SV2002000507A (fr)
TN (1) TNSN01096A1 (fr)
TR (1) TR200401622T4 (fr)
UY (1) UY26797A1 (fr)
WO (1) WO2002000676A1 (fr)
ZA (1) ZA200209557B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2004028530A1 (fr) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company Amines heterocycliques n-substituees, utilisees comme modulateurs de l'activite des recepteurs des chimiokines
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
MX2007003271A (es) * 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
NZ590265A (en) 2008-06-11 2012-11-30 Lasergen Inc Nucleotides and nucleosides and methods for their use in dna sequencing
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
CA2954862A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polytherapie
CA3102279A1 (fr) 2018-06-01 2019-12-05 Cornell University Polytherapie pour maladie ou trouble associe a pi3k
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (fr) * 1986-10-31 1988-05-05 Warner-Lambert Company Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
CA2317093A1 (fr) * 1998-01-08 1999-07-15 Joel M. Linden Agonistes de recepteur d'adenosine a2a
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
PE20020213A1 (es) 2002-03-19
OA12294A (en) 2003-11-14
ECSP024396A (es) 2003-02-06
BR0111912A (pt) 2003-05-13
DK1296996T3 (da) 2004-08-16
TNSN01096A1 (fr) 2005-11-10
HUP0301389A3 (en) 2005-02-28
EA200201291A1 (ru) 2003-04-24
CN1432020A (zh) 2003-07-23
SI1296996T1 (en) 2004-10-31
ZA200209557B (en) 2003-12-02
NO20025975L (no) 2002-12-12
SV2002000507A (es) 2002-07-03
AU2001264164A1 (en) 2002-01-08
BG107171A (bg) 2003-07-31
DE60103537D1 (de) 2004-07-01
PL361384A1 (pl) 2004-10-04
CA2412564C (fr) 2007-10-02
MA26918A1 (fr) 2004-12-20
CZ20023992A3 (cs) 2003-12-17
WO2002000676A1 (fr) 2002-01-03
ATE267836T1 (de) 2004-06-15
GB0015727D0 (en) 2000-08-16
DOP2001000195A (es) 2002-05-15
JP2004501929A (ja) 2004-01-22
ES2220775T3 (es) 2004-12-16
GT200100119A (es) 2002-01-31
HUP0301389A2 (hu) 2003-08-28
MXPA03000078A (es) 2003-08-19
UY26797A1 (es) 2002-01-31
IS6580A (is) 2002-10-10
NO20025975D0 (no) 2002-12-12
NZ521867A (en) 2004-04-30
AP1372A (en) 2005-02-21
CA2412564A1 (fr) 2002-01-03
IL152529A0 (en) 2003-05-29
DE60103537T2 (de) 2005-07-07
HRP20020995A2 (en) 2005-02-28
PA8521001A1 (es) 2002-04-25
PT1296996E (pt) 2004-08-31
TR200401622T4 (tr) 2004-08-23
PY0115244A (es) 2003-11-03
EP1296996B1 (fr) 2004-05-26
SK17332002A3 (sk) 2004-03-02
AR028759A1 (es) 2003-05-21
EP1296996A1 (fr) 2003-04-02
KR20030036248A (ko) 2003-05-09

Similar Documents

Publication Publication Date Title
ATE325807T1 (de) Purinderivate
ATE267836T1 (de) Purinderivate
ATE431356T1 (de) 2-aminocarbonyl-9h-purinderivative
DE60116260D1 (de) Antivirale azaindolderivate
ATE321065T1 (de) Purin-derivate
DK1220863T3 (da) Purinderivater
IS6196A (is) Púrín afleiður
DE60130463D1 (de) Pyrimidin-derivate
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
DK1246791T3 (da) Aminomethyl-phenyl-cyklohexanonderivater
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
EP1295891A4 (fr) Derives de nucleosides